DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Zovia (Ethynodiol Diacetate / Ethinyl Estradiol) - Summary

 
 



ZOVIA SUMMARY

Zovia 1/35E-28
Zovia 1/50E-28
(Ethynodiol Diacetate and Ethinyl Estradiol Tablets USP)
Revised: December 2003
Rx only

Patients should be counseled that this product does not protect against HIV infection (AIDS) and other sexually transmitted diseases.

Zovia 1/35E-28. Each light pink tablet contains 1 mg of ethynodiol diacetate and 35 mcg of ethinyl estradiol.

Zovia 1/50E-28. Each pink tablet contains 1 mg of ethynodiol diacetate and 50 mcg of ethinyl estradiol.

Therapeutic class: Oral contraceptive.

Zovia 1/35E and Zovia 1/50E are indicated for the prevention of pregnancy in women who elect to use oral contraceptives as a method of contraception. Oral contraceptive products such as Zovia 1/50E, which contain 50 mcg of estrogen, should not be used unless medically indicated.


See all Zovia indications & dosage >>

NEWS HIGHLIGHTS

Media Articles Related to Zovia (Ethynodiol / Estradiol)

The benefits of offering counseling and same-day service to women seeking emergency contraception
Source: Sexual Health / STDs News From Medical News Today [2014.04.08]
Health care clinics should routinely offer same-day placement of intrauterine devices (IUDs) to women seeking emergency contraception, according to researchers at the University of Pittsburgh School...

Birth control 'does not result in more promiscuous women'
Source: Sexual Health / STDs News From Medical News Today [2014.03.10]
Despite critics who believe the opposite, a new study has found that providing women with contraception does not encourage them to engage in more risky sexual behavior.

more news >>

Published Studies Related to Zovia (Ethynodiol / Estradiol)

Bioavailability and pharmacokinetics of norethisterone in women after oral doses of ethynodiol diacetate. [1979.02]
PIP: Bioavailability and pharmacokinetics of norethisterone (NE) were studied in 12 women, aged 21-37 years, after oral doses of ethynodiol diacetate (EDA). Plasma NE levels, measured by radioimmunoassay, were used to compare the bioavailability of EDA tablets (Ovulen 50; 1 mg EDA plus .05 mg ethinyl estradiol) with that of a standard oral solution of EDA...

Efficacy and safety of ethynodiol diacetate, 1 mg, with ethinyl estradiol, 35 micrograms, with an emphasis on contraceptive efficacy. A phase IV trial. [1991.04]
A phase IV trial evaluated the efficacy and safety of a monophasic oral contraceptive formulation, ethynodiol diacetate, 1 mg, plus ethinyl estradiol, 35 micrograms (EDA 1 mg with EE 35 micrograms) (Demulen 1/35). Nine hundred eighty-three community-based obstetrician-gynecologists treated a total of 7,759 patients with EDA 1 mg with EE 35 micrograms for one to eight months...

Complexion changes in oral contraceptive users. Results from a phase IV multicenter trial evaluating the safety and efficacy of ethynodiol diacetate, 1 mg, with ethinyl estradiol, 35 micrograms. [1991.04]
An open-label, phase IV, multicenter survey of obstetrician-gynecologists was conducted to evaluate the efficacy and safety of a low-dose monophasic oral contraceptive, ethynodiol diacetate, 1 mg, with ethinyl estradiol, 35 micrograms. Surveys from 983 community-based physicians reported on 6,382 women...

Serum and placenta levels of ethynylestradiol in presence of ethynodiol diacetate after oral administration. [1982.07]
PIP: The ethinyl estradiol concentration--in the presence of ethynodiol diacetate--in serum following oral administration was measured by a rapid radioimmunoassay method developed by the authors. It was found that the peak level was reached 1 hour after administration, and even after 12 hours, a significant amount of free ethinyl estradiol was present in the serum...

more studies >>


Page last updated: 2014-04-08

-- advertisement -- The American Red Cross
 
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2012